US regulators rejected a skin cancer treatment from Replimune Group Inc. in another sign of the agency’s new leadership ...

An analysis from the Congressional Budget Office warns that cuts to the National Institutes of Health and FDA drug reviews could significantly reduce the number of new medications reaching the U.S.

Alzheimer’s disease remains one of medicine’s toughest challenges, affecting millions and costing trillions of dollars ...

Scientists at UCSF and Gladstone Institutes have identified cancer drugs that promise to reverse the changes that occur in ...

A combination of two cancer drugs may provide a pathway to treat Alzheimer’s, according to a study published July 21 in Cell.  Researchers from the University of California San Francisco developed and ...

Scientists at UC San Francisco and Gladstone Institutes have identified cancer drugs that promise to reverse the changes that ...

Sarepta Therapeutics is pausing shipments of its gene therapy for muscular dystrophy following several patient deaths that ...

Study harnesses a cell-type-specific, multi-target drug discovery strategy grounded in human data and real-world evidence.

FDA Commissioner Marty Makary, M.D., has made his pick for the next director of the FDA’s Center for Drug Evaluation and ...

George Francis Tidmarsh, MD, PhD, founding co-director of Stanford’s Master of Translational Research and Applied Medicine ...

Study finds two cancer drugs could slow Alzheimer's disease in mice, offering promise for reversing symptoms in humans.

A Food and Drug Administration expert panel has reignited a debate over whether hormone therapy should be used to treat ...